The central role of endothelial cells in severe angioproliferative pulmonary hypertension

Endothelial Biomedicine

Volumn , Issue , 2007, Pages 1193-1198

  Voelkel, Norbert F ^a   Nicolls, Mark R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 51849118195     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511546198.130     Document Type: Chapter

References (61)

1. Voelkel NF, Tuder RM. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? J Clin Invest. 2000; 106:733-738.
2. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J. 1958;20:557-570.
3. Wagenvoort CA. The pathology of primary pulmonary hyper-tension. J Pathol. 1970;101:i.
4. Voelkel NF, Reeves JT. Primary pulmonary hypertension. In: Moser K, ed. Lung Biology in Health and Disease. New York: Marcel Dekker; 1979:573-628.
5. Loscalzo J. Endothelial dysfunction in pulmonary hypertension. N Engl J Med. 1992;327:117-119.
6. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. EurRespir J. 1998;12:265-270.
7. Groves BM, Turkevich D, Donnellan K, et al. Current approach to treatment of primary pulmonary hypertension. Chest. 1988; 93:S175-S178.
8. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99:1197-1208.
9. Grunig E, Koehler R, Miltenberger-Miltenyi G, et al. Primary pulmonary hypertension in children may have a different genetic background than in adults. Pediatr Res. 2004;56:571-578.
10. Cool CD, Stewart JS, Werahera P, et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol. 1999;155:411-419.
11. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144:275-285.
12. Voelkel NF, Tuder RM. Severe pulmonary hypertensive diseases: a perspective. EurRespir J. 1999;14:1246-1250.
13. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J. 1995;8:2129-2138.
14. Tuder RM, Radisavljevic Z, Shroyer KR, et al. Monoclonal endothelial cells in appetite suppressant-associated pulmonary hypertension. Am J Respir Crit Care Med. 1998;158:1999-2001.
15. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension asso-ciated with scleroderma and human immunodeficiency virus infection. Hum Pathol. 1997;28:434-442.
16. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intra-venous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med. 2000;132:425-434.
17. Karmochkine M, Cacoub P, Dorent R, et al. High prevalence of antiphospholipid antibodies in precapillary pulmonary hyper-tension. J Rheumatol. 1996;23:286-290.
18. LeRoy EC. The heart in systemic sclerosis. NEnglJMed. 1984;310: 188-190.
19. Junod AF. Uptake, metabolism and efflux of 14 C-5-hydroxy-tryptamine in isolated perfused rat lungs. J Pharmacol Exp Ther. 1972;183:341-355.
20. Riggs D, Havill AM, Pitt BR, Gillis CN. Pulmonary angiotensin-converting enzyme kinetics after acute lung injury in the rabbit. J Appl Physiol. 1988;64:2508-2516.
21. Audi SH, Dawson CA, Linehan JH, et al. Pulmonary disposition of lipophilic amine compounds in the isolated perfused rabbit lung. J Appl Physiol. 1998;84:516-530.
22. Voelkel NF, Gerber JG, McMurtry IF, et al. Release ofvasodilator prostaglandin, PGI2, from isolated rat lung during vasoconstriction. CircRes. 1981;48:207-213.
23. Stevens T, Kasper M, Cool C, Voelkel NF. Pulmonary circulation and pulmonary hypertension. In: Aird WC, ed. Endothelial in Health and Disease. New York: Taylor & Francis, 2005:417-437.
24. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles ofvasculogenesis andangiogenesis. Invest Oph-thalmol Vis Sci. 2000;41:1217-1228.
25. Heissig B, Werb Z, Rafii S, Hattori K. Role of c-kit/Kit ligand signaling in regulating vasculogenesis. Thromb Haemost. 2003;90: 570-576.
26. Ono S, Westcott JY, Voelkel NF. PAF antagonists inhibit pul-monary vascular remodeling induced by hypobaric hypoxia in rats. JAppl Physiol. 1992;73:1084-1092.
27. Eddahibi S, Hanoun N, Lanfumey L, et al. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytrypt-amine transporter gene. J Clin Invest. 2000;105:1555-1562.
28. Hoshikawa Y, Ono S, Suzuki S, et al. Generation of oxidative stress contributes to the development of pulmonary hyperten-sion induced by hypoxia. JAppl Physiol. 2001;90:1299-1306.
29. Fanburg BL, Lee SL. A role for the serotonin transporter in hypoxia-induced pulmonary hypertension. J Clin Invest. 2000; 105:1521-1523.
30. Wright L, Tuder RM, Wang J, et al. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med. 1998;157:219-229.
31. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hyper-tension. NEnglJMed. 1993;328:1732-1739.
32. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999; 159:1925-1932.
33. Ameshima S, Golpon H, Cool CD, et al. Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. CircRes. 2003;92:1162-1169.
34. Richter A, Yeager ME, Zaiman A, et al. Impaired transforming growth factor-beta signaling in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170:1340-1348.
35. Lee SD, Shroyer KR, Markham NE, et al. Monoclonal endothe-lial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest. 1998;101: 927-934.
36. Yeager ME, Halley GR, Golpon HA, et al. Microsatellite insta-bility of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension. Circ Res. 2001;88:E2-E11.
37. Tuder RM, Chacon M, Alger L, et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogene-sis. J Pathol. 2001;195:367-374.
38. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 2001;15:427-438.
39. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol. 1991;44:1003-1006.
40. Speich R. Pulmonary infectious complications in HIV disease. Schweiz Rundsch Med Prax. 1994;83:1364-1373.
41. Humbert M, Monti G, Brenot F, et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pul-monary hypertension. Am J Respir Crit Care Med. 1995;151: 1628-1631.
42. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol. 2003; 284:L566-L577.
43. Jung YJ, Isaacs JS, Lee S, et al. IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 2003;17:2115-2117.
44. Wusirika R, Ferri C, Marin M, et al. The assessment of anti-endothelial cell antibodies in scleroderma-associated pulmonary fibrosis. A study of indirect immunofluorescent and western blot analysis in 49 patients with scleroderma. Am J Clin Pathol. 2003;120:596-606.
45. Quismorio FP Jr., Sharma O, Koss M, et al. Immunopatho-logic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum. 1984;13:349-359.
46. Nakagawa N, Osanai S, Ide H, et al. Severe pulmonary hyperten-sion associated with primary Sjogren's syndrome. Intern Med. 2003;42:1248-1252.
47. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219:983-985.
48. Maloney J, Tuder RM, Voelkel NF. Vascular endothelial growth factor binding in the isolated perfused rat lung is decreased by protamine. ATS International Conference, May 21, 1995
49. Sundberg C, Nagy JA, Brown LF, et al. Glomeruloid microvas-cular proliferation follows adenoviral vascular permeability fac-tor/vascular endothelial growth factor-164 gene delivery. Am J Pathol. 2001;158:1145-1160.
50. Voelkel NF, Cool C, Taraceviene-Stewart L, et al. Janus face of vascular endothelial growth factor: the obligatory survival fac-tor for lung vascular endothelium controls precapillary artery remodeling in severe pulmonary hypertension. Crit Care Med. 2002;30:S251-S256.
51. Voelkel N, Taraseviciene-Stewart L. Emphysema: an autoim-mune vascular disease? ProcAm Thorac Soc. 2005;2:23-25.
52. Sakao S, Taraseviciene-Stewart L, Wood K, et al. Apoptosis of pulmonary microvascular endothelial cells stimulates vascular smooth muscle cell growth. Am J Physiol Lung Cell Mol Physiol. 2006;291:L362-368.
53. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothe-lial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem. 1998;273:30336-30343.
54. Hermann C, Zeiher AM, Dimmeler S. Shear stress inhibits H2O2-induced apoptosis of human endothelial cells by modulation of the glutathione redox cycle and nitric oxide synthase. Arterioscler Thromb VascBiol. 1997;17:3588-3592.
55. Glenny RW, Bernard SL, Luchtel DL, et al. Inhibition of VEGF receptor-2 (VEGFR-2) combined with increased shear-stress induces plexiform lesions and pulmonary hypertension in rats. Am J Respir Crit Care Med. 2005;167: A711(Abstract).
56. Sakao S, Taraseviciene-Stewart L, Lee JD, et al. Initial apopto-sis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J. 2005;19(9):1178-1180. Epub 2005 May 16.
57. Cool CD, Rai PR, Yeager ME, et al. Expression of human her-pesvirus 8 in primary pulmonary hypertension. N Engl J Med. 2003;349:1113-1122.
58. Suzuki M, Toyooka S, Shivapurkar N, et al. Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene. 2005;24:1302-1308.
59. Kalantari M, Calleja-Macias IE, Tewari D, et al. Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol. 2004;78: 12762-12772.
60. Renwick N, Weverling GJ, Brouwer J, et al. Vascular endothelial growth factor levels in serum do not increase following HIV type 1 and HHV8 seroconversion and lack correlation with AIDS-related Kaposi's sarcoma. AIDS Res Hum Retroviruses. 2002;18: 695-698.
61. Achcar ROD, Demura Y, Rai PR, et al. Loss ofcaveolin and heme oxygenase expression in severe pulmonary hypertension. Chest. 2006;129(3):696-705.